M Carmen Terencio

List of Publications by Year
in descending order

68	2,287	212478 28	252626 46
papers	citations	h-index	g-index

69	69	69	3403
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Canthaxanthin Biofabrication, Loading in Green Phospholipid Vesicles and Evaluation of In Vitro Protection of Cells and Promotion of Their Monolayer Regeneration. Biomedicines, 2022, 10, 157.	1.4	6
2	Chromogenic Chemodosimeter Based on Capped Silica Particles to Detect Spermine and Spermidine. Nanomaterials, 2021, 11, 818.	1.9	2
3	Annexin A2-Mediated Plasminogen Activation in Endothelial Cells Contributes to the Proangiogenic Effect of Adenosine A2A Receptors. Frontiers in Pharmacology, 2021, 12, 654104.	1.6	10
4	Oleuropein multicompartment nanovesicles enriched with collagen as a natural strategy for the treatment of skin wounds connected with oxidative stress. Nanomedicine, 2021, 16, 2363-2376.	1.7	11
5	Peptideâ€Capped Mesoporous Nanoparticles: Toward a more Efficient Internalization of Alendronate. ChemistrySelect, 2020, 5, 3618-3625.	0.7	2
6	Osteostatin Inhibits Collagen-Induced Arthritis by Regulation of Immune Activation, Pro-Inflammatory Cytokines, and Osteoclastogenesis. International Journal of Molecular Sciences, 2019, 20, 3845.	1.8	8
7	Defective Induction of COX-2 Expression by Psoriatic Fibroblasts Promotes Pro-inflammatory Activation of Macrophages. Frontiers in Immunology, 2019, 10, 536.	2.2	22
8	Nanodesign of new self-assembling core-shell gellan-transfersomes loading baicalin and in vivo evaluation of repair response in skin. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 569-579.	1.7	46
9	Topical Application of Glycolipids from Isochrysis galbana Prevents Epidermal Hyperplasia in Mice. Marine Drugs, 2018, 16, 2.	2.2	22
10	Ex Vivo Tracking of Endogenous CO with a Ruthenium(II) Complex. Journal of the American Chemical Society, 2017, 139, 18484-18487.	6.6	74
11	Adenosine A2A and A2B Receptors Differentially Modulate Keratinocyte Proliferation: Possible Deregulation in Psoriatic Epidermis. Journal of Investigative Dermatology, 2017, 137, 123-131.	0.3	24
12	Chondroprotective effects of the combination chondroitin sulfate-glucosamine in a model of osteoarthritis induced by anterior cruciate ligament transection in ovariectomised rats. Biomedicine and Pharmacotherapy, 2016, 79, 120-128.	2.5	24
13	Decreased <scp>SAPK</scp>/<scp>JNK</scp> signalling affects cytokine release and <scp>STAT</scp>3 activation in psoriatic fibroblasts. Experimental Dermatology, 2015, 24, 800-802.	1.4	7
14	A Boron Dipyrromethene (BODIPY)â€Based Cu^{II}â€“Bipyridine Complex for Highly Selective NO Detection. Chemistry - A European Journal, 2015, 21, 15486-15490.	1.7	19
15	Effects of BIS076 in a model of osteoarthritis induced by anterior cruciate ligament transection in ovariectomised rats. BMC Musculoskeletal Disorders, 2015, 16, 92.	0.8	9
16	Influence of age on osteoarthritis progression after anterior cruciate ligament transection in rats. Experimental Gerontology, 2014, 55, 44-48.	1.2	18
17	Topical application of the adenosine A_{2A} receptor agonist <scp>CGS</scp>â€21680 prevents phorbolâ€induced epidermal hyperplasia and inflammation in mice. Experimental Dermatology, 2014, 23, 555-560.	1.4	19
18	Potential antipsoriatic effect of chondroitin sulfate through inhibition of NF-ÎºB and STAT3 in human keratinocytes. Pharmacological Research, 2013, 70, 20-26.	3.1	18

#	Article	IF	Citations
19	NF-ÎºB and STAT3 Inhibition as a Therapeutic Strategy in Psoriasis: In Vitro and In Vivo Effects of BTH. Journal of Investigative Dermatology, 2013, 133, 2362-2371.	0.3	85
20	Analysis of early biochemical markers and regulation by tin protoporphyrin IX in a model of spontaneous osteoarthritis. Experimental Gerontology, 2012, 47, 406-409.	1.2	15
21	Perthamides Câ€“F, potent human antipsoriatic cyclopeptides. Tetrahedron, 2011, 67, 7780-7786.	1.0	20
22	A new chloroquinolinyl chalcone derivative as inhibitor of inflammatory and immune response in mice and rats. Journal of Pharmacy and Pharmacology, 2010, 55, 1313-1321.	1.2	9
23	Anti-inflammatory and analgesic activity of a novel inhibitor of microsomal prostaglandin E synthase-1 expression. European Journal of Pharmacology, 2009, 620, 112-119.	1.7	37
24	Coscinolactams A and B: new nitrogen-containing sesterterpenoids from the marine sponge Coscinoderma mathewsi exerting anti-inflammatory properties. Tetrahedron, 2009, 65, 2905-2909.	1.0	25
25	Avarol inhibits TNF-Î± generation and NF-ÎºB activation in human cells and in animal models. Life Sciences, 2008, 82, 256-264.	2.0	32
26	Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2/5-lipoxygenase inhibitor. Life Sciences, 2007, 80, 2108-2117.	2.0	42
27	Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis. Annals of the Rheumatic Diseases, 2007, 67, 1211-1217.	0.5	78
28	Antipsoriatic effects of avarolâ€3â€²â€thiosalicylate are mediated by inhibition of TNFâ€Î±generation and NFâ€ÎºB activation in mouse skin. British Journal of Pharmacology, 2007, 152, 353-365.	2.7	33
29	Heme oxygenase-1 inhibits apoptosis in Caco-2 cells via activation of Akt pathway. International Journal of Biochemistry and Cell Biology, 2006, 38, 1510-1517.	1.2	91
30	Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase. Life Sciences, 2006, 78, 2911-2918.	2.0	28
31	Identification of avarol derivatives as potential antipsoriatic drugs using an in vitro model for keratinocyte growth and differentiation. Life Sciences, 2006, 79, 2395-2404.	2.0	23
32	Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis. Arthritis and Rheumatism, 2005, 52, 3230-3238.	6.7	71
33	Role of nuclear factor-Îº B and heme oxygenase-1 in the mechanism of action of an anti-inflammatory chalcone derivative in RAW 264.7 cells. British Journal of Pharmacology, 2004, 142, 1191-1199.	2.7	73
34	Potential Antipsoriatic Avarol Derivatives as Antioxidants and Inhibitors of PGE2Generation and Proliferation in the HaCaT Cell Line. Journal of Natural Products, 2004, 67, 1459-1463.	1.5	33
35	Inhibition of the NF-ÎºB signaling pathway mediates the anti-inflammatory effects of petrosaspongiolide M. Biochemical Pharmacology, 2003, 65, 887-895.	2.0	32
36	Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-Î± by inhibiting nuclear factor-Îº B activation. British Journal of Pharmacology, 2003, 138, 1571-1579.	2.7	32

#	Article	IF	Citations
37	1-(2,3,4-trimethoxyphenyl)-3-(3-(2-chloroquinolinyl))-2-propen-1-one, a chalcone derivative with analgesic, anti-inflammatory and immunomodulatory properties. Inflammation Research, 2003, 52, 246-257.	1.6	27
38	Diayangambin Exerts Immunosuppressive and Anti-Inflammatory Effectsin vitroandin vivo. Planta Medica, 2002, 68, 1128-1131.	0.7	31
39	A pyrroloquinazoline derivative with anti-inflammatory and analgesic activity by dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase. European Journal of Pharmacology, 2002, 434, 177-185.	1.7	22
40	A new ditriazine inhibitor of NF-Î¹B modulates chronic inflammation and angiogenesis. Naunyn-Schmiedeberg's Archives of Pharmacology, 2002, 365, 357-364.	1.4	5
41	Solid-Phase Synthesis and Inhibitory Effects of Some Pyrido[1,2-c]pyrimidine Derivatives on Leukocyte Functions and Experimental Inflammation. Journal of Medicinal Chemistry, 2001, 44, 1011-1014.	2.9	46
42	Inhibition of Leukocyte Functions by the Alkaloid Isaindigotone fromIsatis indigoticaand Some New Synthetic Derivatives. Journal of Natural Products, 2001, 64, 1297-1300.	1.5	52
43	Inhibition of 5-lipoxygenase activity by the natural anti-inflammatory compound aethiopinone. Inflammation Research, 2001, 50, 96-101.	1.6	35
44	Dysidotronic acid, a new sesquiterpenoid, inhibits cytokine production and the expression of nitric oxide synthase. European Journal of Pharmacology, 2001, 415, 285-292.	1.7	9
45	An anti-inflammatory ditriazine inhibiting leukocyte functions and expression of inducible nitric oxide synthase and cyclo-oxygenase-2. European Journal of Pharmacology, 2000, 397, 207-217.	1.7	16
46	Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361, 98-106.	1.4	178
47	Cavernolide. Life Sciences, 2000, 67, 3007-3014.	2.0	18
48	Synthesis and Pharmacological Evaluation of Some 8-Cyanopyrido[3â€˜,2â€˜:4,5]thieno[3,2-d]triazine Derivatives as Inhibitors of Nitric Oxide and Eicosanoid Biosynthesis. Journal of Medicinal Chemistry, 1999, 42, 4720-4724.	2.9	16
49	Inhibition of human sPLA2 and 5-lipoxygenase activities by two neo-clerodane diterpenoids. Life Sciences, 1999, 64, PL205-PL211.	2.0	15
50	Suppression of leukotriene B4 and tumour necrosis factor Î± release in acute inflammatory responses by novel prenylated hydroquinone derivatives. Naunyn-Schmiedeberg's Archives of Pharmacology, 1998, 357, 565-572.	1.4	24
51	A New Cacospongionolide Inhibitor of Human Secretory Phospholipase A2from the Tyrrhenian SpongeFasciospongia cavernosaand Absolute Configuration of Cacospongionolides. Journal of Natural Products, 1998, 61, 931-935.	1.5	41
52	Anti-inflammatory activity in mice of extracts from mediterranean marine invertebrates. Life Sciences, 1998, 62, PL115-PL120.	2.0	24
53	Morelloflavone, a novel biflavonoid inhibitor of human secretory phospholipase A2 with anti-inflammatory activity. Biochemical Pharmacology, 1997, 53, 733-740.	2.0	90
54	Diclofenac sodium and cyclosporin A inhibit human lens epithelial cell proliferation in culture. Graefe's Archive for Clinical and Experimental Ophthalmology, 1997, 235, 180-185.	1.0	49

#	Article	IF	Citations
55	Involvement of secretory phospholipase A₂ activity in the zymosan rat air pouch model of inflammation. British Journal of Pharmacology, 1996, 117, 1773-1779.	2.7	49
56	Inhibition of inflammatory responses by a series of novel dolabrane derivatives. European Journal of Pharmacology, 1996, 312, 97-105.	1.7	11
57	Inhibition of phospholipase A2 activities and some inflammatory responses by the marine product ircinin. Naunyn-Schmiedeberg's Archives of Pharmacology, 1996, 354, 677-683.	1.4	19
58	Antioxidant Profile of Mono-and Dihydroxylated Flavone Derivatives in Free Radical Generating Systems. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 1995, 50, 552-560.	0.6	29
59	Immunochemical detection of protein adducts in cultured human hepatocytes exposed to diclofenac. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1995, 1272, 140-146.	1.8	28
60	Inhibition of inflammatory responses by epitaondiol and other marine natural products. Life Sciences, 1995, 57, PL25-PL30.	2.0	40
61	Effects of marine 2-polyprenyl-1,4-hydroquinones on phospholipase A2 activity and some inflammatory responses. European Journal of Pharmacology, 1995, 285, 281-288.	1.7	27
62	Influence of a series of natural flavonoids on free radical generating systems and oxidative stress. Xenobiotica, 1994, 24, 689-699.	0.5	163
63	Accelerated communication: Effects of flavonoids on Naja Naja and human recombinant synovial phospholipases A2 and inflammatory responses in mice. Life Sciences, 1994, 54, PL333-PL338.	2.0	78
64	On the Occurrence of Caffeoyltartronic Acid and Other Phenolics in Chondrilla juncea. Zeitschrift Fur Naturforschung - Section C Journal of Biosciences, 1993, 48, 417-419.	0.6	6
65	Antihypertensive action of a procyanidin glycoside from Rhamnus lycioides. Journal of Ethnopharmacology, 1991, 31, 109-114.	2.0	26
66	A hypotensive procyanidin-glycoside from Rhamnus lycioides ssp. lycioides. Journal of Ethnopharmacology, 1990, 30, 205-214.	2.0	4
67	In vivo hypotensive activity ofPistacia lentiscus L. Phytotherapy Research, 1988, 2, 201-203.	2.8	4
68	Hypotensive effect of Rhamnus lycioides extracts. Journal of Ethnopharmacology, 1986, 16, 269-273.	2.0	5